SUPN Quote, Financials, Valuation and Earnings

Bristol-Myers Squibb has a net margin of -7.89% compared to Supernus Pharmaceuticals's net margin of 21.93%. Supernus Pharmaceuticals's return on equity of 6.24% beat Bristol-Myers Squibb's return on equity of 32.01%.

Supernus Pharmaceuticals has a consensus price target of $39.00, signalling upside risk potential of 16.35%. On the other hand Bristol-Myers Squibb has an analysts' consensus of $57.01 which suggests that it could grow by 20.85%. Given that Bristol-Myers Squibb has higher upside potential than Supernus Pharmaceuticals, analysts believe Bristol-Myers Squibb is more attractive than Supernus Pharmaceuticals.

Supernus Pharmaceuticals has a beta of 0.700, which suggesting that the stock is 30.01% less volatile than S&P 500. In comparison Bristol-Myers Squibb has a beta of 0.363, suggesting its less volatile than the S&P 500 by 63.75%.

Supernus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bristol-Myers Squibb offers a yield of 5.22% to investors and pays a quarterly dividend of $0.62 per share. Supernus Pharmaceuticals pays -- of its earnings as a dividend. Bristol-Myers Squibb pays out -54.35% of its earnings as a dividend.

Supernus Pharmaceuticals quarterly revenues are $149.8M, which are smaller than Bristol-Myers Squibb quarterly revenues of $11.2B. Supernus Pharmaceuticals's net income of -$11.8M is lower than Bristol-Myers Squibb's net income of $2.5B. Notably, Supernus Pharmaceuticals's price-to-earnings ratio is 30.20x while Bristol-Myers Squibb's PE ratio is 17.67x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals is 2.81x versus 2.01x for Bristol-Myers Squibb. Usually stocks with elevated PS ratios are considered overvalued.

Eli Lilly and has a net margin of -7.89% compared to Supernus Pharmaceuticals's net margin of 21.68%. Supernus Pharmaceuticals's return on equity of 6.24% beat Eli Lilly and's return on equity of 78.25%.

Supernus Pharmaceuticals has a consensus price target of $39.00, signalling upside risk potential of 16.35%. On the other hand Eli Lilly and has an analysts' consensus of $952.27 which suggests that it could grow by 20.57%. Given that Eli Lilly and has higher upside potential than Supernus Pharmaceuticals, analysts believe Eli Lilly and is more attractive than Supernus Pharmaceuticals.

Supernus Pharmaceuticals has a beta of 0.700, which suggesting that the stock is 30.01% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.405, suggesting its less volatile than the S&P 500 by 59.528%.

Supernus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Eli Lilly and offers a yield of 0.71% to investors and pays a quarterly dividend of $1.50 per share. Supernus Pharmaceuticals pays -- of its earnings as a dividend. Eli Lilly and pays out 44.2% of its earnings as a dividend. Eli Lilly and's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Supernus Pharmaceuticals quarterly revenues are $149.8M, which are smaller than Eli Lilly and quarterly revenues of $12.7B. Supernus Pharmaceuticals's net income of -$11.8M is lower than Eli Lilly and's net income of $2.8B. Notably, Supernus Pharmaceuticals's price-to-earnings ratio is 30.20x while Eli Lilly and's PE ratio is 64.26x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals is 2.81x versus 14.56x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

Sage Therapeutics has a net margin of -7.89% compared to Supernus Pharmaceuticals's net margin of -442.4%. Supernus Pharmaceuticals's return on equity of 6.24% beat Sage Therapeutics's return on equity of -64.19%.

Supernus Pharmaceuticals has a consensus price target of $39.00, signalling upside risk potential of 16.35%. On the other hand Sage Therapeutics has an analysts' consensus of $8.73 which suggests that it could fall by -4.4%. Given that Supernus Pharmaceuticals has higher upside potential than Sage Therapeutics, analysts believe Supernus Pharmaceuticals is more attractive than Sage Therapeutics.

Supernus Pharmaceuticals has a beta of 0.700, which suggesting that the stock is 30.01% less volatile than S&P 500. In comparison Sage Therapeutics has a beta of 0.294, suggesting its less volatile than the S&P 500 by 70.557%.

Supernus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sage Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Supernus Pharmaceuticals pays -- of its earnings as a dividend. Sage Therapeutics pays out -- of its earnings as a dividend.

Supernus Pharmaceuticals quarterly revenues are $149.8M, which are larger than Sage Therapeutics quarterly revenues of $14.1M. Supernus Pharmaceuticals's net income of -$11.8M is higher than Sage Therapeutics's net income of -$62.2M. Notably, Supernus Pharmaceuticals's price-to-earnings ratio is 30.20x while Sage Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals is 2.81x versus 11.79x for Sage Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

Sarepta Therapeutics has a net margin of -7.89% compared to Supernus Pharmaceuticals's net margin of -60.08%. Supernus Pharmaceuticals's return on equity of 6.24% beat Sarepta Therapeutics's return on equity of -20.94%.

Supernus Pharmaceuticals has a consensus price target of $39.00, signalling upside risk potential of 16.35%. On the other hand Sarepta Therapeutics has an analysts' consensus of $44.54 which suggests that it could grow by 144.39%. Given that Sarepta Therapeutics has higher upside potential than Supernus Pharmaceuticals, analysts believe Sarepta Therapeutics is more attractive than Supernus Pharmaceuticals.

Supernus Pharmaceuticals has a beta of 0.700, which suggesting that the stock is 30.01% less volatile than S&P 500. In comparison Sarepta Therapeutics has a beta of 0.448, suggesting its less volatile than the S&P 500 by 55.179%.

Supernus Pharmaceuticals has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sarepta Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Supernus Pharmaceuticals pays -- of its earnings as a dividend. Sarepta Therapeutics pays out -- of its earnings as a dividend.

Supernus Pharmaceuticals quarterly revenues are $149.8M, which are smaller than Sarepta Therapeutics quarterly revenues of $744.9M. Supernus Pharmaceuticals's net income of -$11.8M is higher than Sarepta Therapeutics's net income of -$447.5M. Notably, Supernus Pharmaceuticals's price-to-earnings ratio is 30.20x while Sarepta Therapeutics's PE ratio is 20.50x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Supernus Pharmaceuticals is 2.81x versus 0.91x for Sarepta Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.